155.51
前日終値:
$153.75
開ける:
$154.47
24時間の取引高:
893.06K
Relative Volume:
0.95
時価総額:
$15.51B
収益:
$2.41B
当期純損益:
$305.80M
株価収益率:
52.72
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
+2.20%
1か月 パフォーマンス:
+1.14%
6か月 パフォーマンス:
+24.80%
1年 パフォーマンス:
+23.01%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
155.51 | 15.38B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
118.65 | 53.06B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.18 | 45.11B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.44B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.46 | 32.59B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
489.31 | 20.84B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
TD Cowen Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Earnings Recap: How Neurocrine Biosciences Inc stock performs in weak economyWeekly Trade Report & High Accuracy Trade Alerts - BỘ NỘI VỤ
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Brown Advisory Inc. - MarketBeat
TD Cowen Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Saturn V Capital Management LP Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Will Neurocrine Biosciences Inc. stock split again soonWeekly Loss Report & Free Fast Gain Swing Trade Alerts - Newser
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen By Investing.com - Investing.com South Africa
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen - Investing.com India
Why Neurocrine Biosciences Inc. (NB3) stock stays on buy listsPortfolio Gains Summary & High Accuracy Trade Signal Alerts - Newser
Dodge & Cox Increases Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
U.S. Tardive Dyskinesia Treatment Market to Reach USD 6417.43 - openPR.com
Will Neurocrine Biosciences Inc. (NB3) stock beat growth indexesOil Prices & Accurate Technical Buy Alerts - Newser
Lyons (Neurocrine Biosciences director) sells $2.29m in NBIX stock - Investing.com
Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing - marketscreener.com
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockWeekly Trend Summary & Real-Time Buy Zone Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyDollar Strength & Growth Oriented Trade Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityDividend Hike & Precise Entry and Exit Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock benefit from sector leadershipPortfolio Profit Report & Expert Verified Stock Movement Alerts - Newser
Will Neurocrine Biosciences Inc. (NB3) stock gain from green policies2025 Institutional Moves & Weekly High Potential Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock remains top ratedMarket Trend Summary & Daily Technical Forecast Reports - Newser
Fisher Asset Management LLC Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - The Motley Fool
Sio Capital Management LLC Lowers Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Mackenzie Financial Corp Has $9.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Norges Bank Takes Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hsbc Holdings PLC - MarketBeat
Korea Investment CORP Cuts Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Russell Investments Group Ltd. Has $10.58 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Can Neurocrine Biosciences Inc. stock attract ESG capital inflowsJuly 2025 Drop Watch & Consistent Growth Stock Picks - Newser
Neurocrine Biosciences fails mid-stage study of depression drug - MSN
Neurocrine Biosciences Insider Sold Shares Worth $905,881, According to a Recent SEC Filing - marketscreener.com
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Virtus Advisers LLC - MarketBeat
Loomis Sayles & Co. L P Acquires New Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZA’s Clinical Profile - simplywall.st
Edgestream Partners L.P. Takes $9.25 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Distillate Capital Partners LLC Sells 8,175 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusQuarterly Profit Report & Growth Focused Entry Reports - Newser
Deutsche Bank Raises Price Target on Neurocrine Biosciences to $152 From $142, Keeps Hold Rating - marketscreener.com
Skandinaviska Enskilda Banken AB publ Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Quadrature Capital Ltd Purchases 11,162 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Inceptionr LLC Takes Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Charles Schwab Investment Management Inc. Purchases 13,942 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
(NBIX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Capital Fund Management S.A. Grows Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation Following New Narrative Review on VMAT2 Therapies - simplywall.st
Neurocrine Bio. stock jumps as rival drug faces modest Medicare price cut - Investing.com Canada
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by CreativeOne Wealth LLC - MarketBeat
Prudential Financial Inc. Purchases 26,030 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication - Yahoo Finance
Advisors Asset Management Inc. Cuts Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Creative Planning Raises Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):